George Kelly, MD
Rheumatology · Las Vegas, NVNPI 1619944113
Payments from drug & device makers
Across 1,269 payments — averaging $881.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$315K
- UCB SA$293K
- AbbVie$265K
- Amgen$64K
- Pfizer$48K
- Novartis$32K
- plus $102K from 25 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 17 | $315,091 |
| UCB SA | 19 | $292,962 |
| AbbVie | 294 | $264,978 |
| Amgen(2 entities) | 158 | $63,835 |
| Pfizer | 44 | $47,891 |
| Novartis | 129 | $32,131 |
| Eli Lilly | 5 | $28,617 |
| GSK | 74 | $22,412 |
| Mallinckrodt Enterprises LLC | 4 | $15,332 |
| E.r. Squibb & Sons, L.L.C. | 69 | $12,488 |
| Lilly USA, LLC | 70 | $8,667 |
| AstraZeneca(2 entities) | 15 | $6,099 |
| UCB, Inc. | 116 | $3,314 |
| Johnson & Johnson | 117 | $1,669 |
| Genentech USA, Inc. | 30 | $462 |
| Aurinia Pharma U.S., Inc. | 7 | $429 |
| Organon | 17 | $366 |
| ANI Pharmaceuticals, Inc. | 15 | $365 |
| Radius Health, Inc. | 17 | $356 |
| Sanofi | 8 | $355 |
| Boehringer Ingelheim | 6 | $215 |
| Mallinckrodt Hospital Products Inc. | 9 | $182 |
| Sobi, Inc | 9 | $174 |
| Sandoz | 7 | $163 |
| Kyowa Kirin, Inc. | 4 | $94 |
| Teva Pharmaceuticals USA, Inc. | 3 | $53 |
| Tersera Therapeutics LLC | 1 | $46 |
| Bristol Myers Squibb | 2 | $43 |
| Fresenius Kabi USA, LLC | 1 | $31 |
| Medexus Pharma, Inc. | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
How this compares
$1,118,854 in reported general payments places this provider in the 95th percentile of 43 rheumatology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other rheumatology in Las Vegas
- Sandra PagnussatLas Vegas$28.3M
- Walter ChathamLas Vegas$2.2M
- Ewa OlechLas Vegas$297K
- William KimLas Vegas$183K
- Nasim DaoudLas Vegas$109K
- Aida LoudyiLas Vegas$10K
- Tudor JianuLas Vegas$8K
- Khalil Ibrahim BourjiLas Vegas$7K
- Neil BraunsteinLas Vegas$6K
- Michael CliffordLas Vegas$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.